Cargando…
TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial
BACKGROUND: Cervical dysplasia (cervical intraepithelial neoplasia (CIN)) is caused by Human Papillomavirus (HPV) and is most common in women of reproductive age. Current treatment of moderate to severe CIN is surgical. This procedure has potential complications, such as haemorrhage, infection and p...
Autores principales: | van de Sande, A. J. M., Koeneman, M. M., Gerestein, C. G., Kruse, A. J., van Kemenade, F. J., van Beekhuizen, H. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003116/ https://www.ncbi.nlm.nih.gov/pubmed/29902979 http://dx.doi.org/10.1186/s12885-018-4510-7 |
Ejemplares similares
-
Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial
por: Koeneman, M. M., et al.
Publicado: (2017) -
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial
por: Koeneman, M. M., et al.
Publicado: (2016) -
Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series
por: Wouters, Tirza, et al.
Publicado: (2019) -
Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study
por: Hendriks, Natasja, et al.
Publicado: (2022) -
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions
por: Abdulrahman, Ziena, et al.
Publicado: (2022)